NGNE Earnings & Financial Statements
Neurogene Inc.
$23.54
+$1.36(+6.13%)
38
Overall
--
Value
45
Tech
31
Quality
Market Cap
$443.85M
Volume
80.10K
52W Range
$15.93 - $43.66
Target Price
$77.22
NGNE earnings and financial statements: Neurogene Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
NGNE Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | $925.0K | - | - | - |
| Operating income | -$103.33M | -$82.61M | -$55.58M | -$56.52M | -$60.70M |
| EBITDA | -$87.35M | -$71.84M | -$32.97M | -$51.99M | -$49.57M |
| Net income | -$90.40M | -$75.10M | -$36.32M | -$55.19M | -$50.52M |
| EPS (diluted) | $-4.24 | $-4.28 | $-7.80 | $-4.16 | $-4.40 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $288.60M | $335.73M | $222.57M | $109.27M | $163.26M |
| Total liabilities | $23.72M | $25.36M | $36.55M | $10.64M | $20.40M |
| Shareholders’ equity | $264.89M | $310.38M | $186.02M | -$145.74M | $142.86M |
| Cash and equivalents | $103.84M | $136.59M | $148.21M | $82.02M | $142.47M |
| Long-term debt | $6.83M | $9.43M | $12.37M | $3.99M | $11.76M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$77.20M | -$70.60M | -$51.40M | -$52.82M | -$46.40M |
| Capital expenditure | -$1.18M | -$808.0K | -$321.0K | -$2.23M | -$18.37M |
| Free cash flow | -$78.38M | -$71.41M | -$51.72M | -$55.05M | -$64.77M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NGNE | $23.54 | +6.1% | 80.10K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |